期刊文献+

非小细胞肺癌的中西医结合治疗探讨 被引量:1

Investigation of Combined Traditional Chinese and Western Medicine Treatment of Non- small Cell Lung Cancer
下载PDF
导出
摘要 西医治疗肺癌的主要手段在于手术、放化疗和分子靶向治疗。虽然技术不断革新,也不断出现新的分子靶向性药物,但该类治疗易于复发和转移,并且会不断产生抗药性。中医治疗肺癌倾向于扶正与祛邪并重,而且中医的"辨证施治"更能发挥"个体化治疗"的优势。将西医的早期诊断、靶向性治疗与中医的辨证论治、整体调理相结合,不仅有利于提高肺癌的临床疗效,改善病人的生活质量。另外,通过有效病例的积累,还将为探明肺癌的发生、发展机制提供宝贵的一手资料。由此必将推动肺癌的治疗从治疗手段的中西医结合到理论认识水平的中西医结合,从而使肺癌的临床治疗获得得更大的突破性进展。 The main approaches of Western Medicine treatment of lung cancer is surgery,radiation,chemotherapy and molecular targeted therapy. Despite of the innovation of the technology and emergence of new targeted molecular drugs,recurrence,metastasis and resistance to the medicine are still the severe problems. Treatment of lung cancer through traditional Chinese medicine favorites strengthening healthy qi and eliminating pathogens. Furthermore,diagnosis and treatment based on an overall analysis of the illness and the patient's condition have the advantage of personality. Early diagnosis and targeted treatment by Western medicine combined with syndrome differentiation and whole regulation of traditional Chinese medicine is beneficial to improving the clinical curative effects and patient's quality of life. Moreover,an accumulation of effective cases will also provide valuable first- hand material for investigation of the occurrence and development mechanisms of lung cancer. This will be beneficial for promoting the combination of traditional Chinese medicine and Western medicine treatment theoretically and technically,and largely push the development of clinical treatment of lung cancer.
出处 《中华中医药学刊》 CAS 北大核心 2015年第11期2697-2699,共3页 Chinese Archives of Traditional Chinese Medicine
基金 江苏省自然科学基金项目(BK20131415) 江苏高校优势学科建设工程项目 南京中医药大学基础医学院青年科技创新基金项目(14JCQN05)
关键词 中西医结合 肺癌 非小细胞肺癌 combined traditional Chinese and Western medicine lung cancer non-small cell lung cancer(NSCLC)
  • 相关文献

参考文献28

  • 1方涛,初向阳.分子靶向治疗与EGFR基因突变在非小细胞肺癌中的研究进展[J].实用临床医药杂志,2010,14(1):9-12. 被引量:9
  • 2阮纪恺.肺癌的中西医结合治疗新进展[J].中医学报,2010,25(2):218-220. 被引量:8
  • 3Sanders HR, Albitar M. Somatic mutations of signaling genes in non - small - cell lung cancer[ J]. Cancer Genet Cytogen,2010, 203:7 - 15.
  • 4Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non - small - cell lung cancer to gefitinib [ J ]. N Engl J Med,2005,352(8) :786 92.
  • 5Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung to gefitinib or erlotinib is associated with a sec- ond mutation in the EGFR kinase domain [ J ]. PLOS Med, 2005, 2 ( 3 ) :225 - 235.
  • 6Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T'/90M mutations in epidermal growth factor receptor - mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [ J ]. Clin Cancer Res,2006,12 ( 21 ) :6494 - 6501.
  • 7Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non - small cell lung cancer and acquired resistance to gefitinib [ J ]. Clin Cancer Res ,2006,12 ( 19 ) :5764 - 5769.
  • 8Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor over- comes resistance caused by a mutation of the epidermal growth factor receptor [ J ]. Cancer Res, 2005,65 ( 16 ) :7096 - 7101.
  • 9Engelman JA, Mukohara T, Zejnullahu K,et al. Allelic dilutionobscures detection of a biologically significant resistance mutation in EGFR- amplified lung cancer [ J ]. J Clin Invest ,2006,116 (10) :2695 - 2706.
  • 10Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan -ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [ J ]. Cancer Res,2007,67 (24) : 11924 - 11932.

二级参考文献153

共引文献166

同被引文献13

引证文献1

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部